Shield Therapeutics plc
STX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £25 | £13 | £5 | £2 |
| % Growth | 92.5% | 138% | 262% | – |
| Cost of Goods Sold | £15 | £9 | £2 | £1 |
| Gross Profit | £11 | £4 | £2 | £1 |
| % Margin | 42% | 30.8% | 36.3% | 35.5% |
| R&D Expenses | £1 | £2 | £1 | £1 |
| G&A Expenses | £11 | £15 | £27 | £20 |
| SG&A Expenses | £27 | £37 | £27 | £20 |
| Sales & Mktg Exp. | £24 | £22 | £0 | £0 |
| Other Operating Expenses | £9 | -£3 | -£1 | -£0 |
| Operating Expenses | £38 | £35 | £28 | £20 |
| Operating Income | -£18 | -£31 | -£26 | -£20 |
| % Margin | -71.4% | -239.4% | -479.9% | -1,343.3% |
| Other Income/Exp. Net | -£3 | -£1 | -£14 | £0 |
| Pre-Tax Income | -£21 | -£32 | -£40 | -£20 |
| Tax Expense | £0 | £1 | £0 | -£0 |
| Net Income | -£21 | -£33 | -£40 | -£19 |
| % Margin | -84.5% | -254.4% | -735.5% | -1,272.9% |
| EPS | -0.024 | -0.037 | -0.17 | -0.095 |
| % Growth | 36.7% | 78.2% | -79.7% | – |
| EPS Diluted | -0.024 | -0.037 | -0.17 | -0.095 |
| Weighted Avg Shares Out | 905 | 723 | 233 | 204 |
| Weighted Avg Shares Out Dil | 905 | 723 | 233 | 204 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £3 | £1 | £0 | £0 |
| Depreciation & Amortization | £1 | £1 | £3 | £2 |
| EBITDA | -£17 | -£30 | -£46 | -£18 |
| % Margin | -65.8% | -231.5% | -837.7% | -1,164.7% |